Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma

BACKGROUND. Vemurafenib has been approved for the treatment of patients with advanced BRAF(V600E)-mutant melanoma. This report by the Vemurafenib Dermatology Working Group presents the characteristics of dermatologic adverse events (AEs) that occur in vemurafenib-treated patients, including cutaneou...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Lacouture, Mario E., Duvic, Madeleine, Hauschild, Axel, Prieto, Victor G., Robert, Caroline, Schadendorf, Dirk, Kim, Caroline C., McCormack, Christopher J., Myskowski, Patricia L., Spleiss, Olivia, Trunzer, Kerstin, Su, Fei, Nelson, Betty, Nolop, Keith B., Grippo, Joseph F., Lee, Richard J., Klimek, Matthew J., Troy, James L., Joe, Andrew K.
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2013
Témata:
Melanoma and Cutaneous Malignancies
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3607529/
https://ncbi.nlm.nih.gov/pubmed/23457002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0333
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky